Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Gynecologic Cancers

“Compared to those not enrolled in clinical trials, the evidence shows that the minority patients participating in clinical trials had increased overall survival,” said Khilen B. Patel, MD, at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Angiogenesis is an active area of clinical research in ovarian cancer, but proving that this approach extends overall survival (OS) has been somewhat challenging thus far.
Neoadjuvant chemotherapy was found equivalent to primary surgery followed by chemotherapy for patients with advanced ovarian cancer in the Medical Research Council Chemotherapy Or Upfront Surgery (MRC CHORUS) trial reported at the 2013 American Society of Clinical Oncology Annual Meeting.
A list of resources arranged and provided for patients, survivors, providers, researchers and supporters in the field of Oncology.
Previous trials of maintenance therapy for patients with ovarian cancer have failed to show improved survival. A study presented at the 2013 American Society of Clinical Oncology Annual Meeting is the first successful phase 3 trial in this setting—targeted therapy pazopanib extended progression-free survival (PFS) in women with ovarian cancer by a median of 5.6 months.
T-DM1 was the first antibody-drug conjugate to gain US Food and Drug Administration approval for HER2 (human epidermal growth factor 2)-positive metastatic breast cancer.
According to a retrospective review of more than 13,000 cases, most women with ovarian cancer received substandard care that significantly reduced their survival odds.

Each year, more than 2 million Americans face a new diagnosis of skin cancer. Some 50,000 patients receive a diagnosis of melanoma. Regular skin checks, however, can assist in discovering melanoma at its earliest stages.

Ovarian cancer is said to “whisper,” because the symptoms are seldom obvious. The most frequent symptoms seen in women diagnosed with ovarian cancer are abdominal bloating, pelvic or abdominal pain, difficulty eating/feeling full fast, or urinary symptoms. These are often passed off as nothing other than symptoms of getting older, gaining weight, or related to menopause. However, this whispering disease is the most lethal of all the breast and gynecologic cancers and accounts for more deaths than any other cancer of the female reproductive system.1

Late-stage ovarian cancer patients responded well to an experimental carboplatin/decitabine combination therapy, even though they had become resistant to carboplatin, Indiana University researchers report. Furthermore, the researchers believe they have discovered biomarkers that could assist in identifying patients who are most likely to benefit from this therapy. 

Page 1 of 2
Results 1 - 10 of 14